Cargando…
Denosumab Safety and Efficacy Among Participants in the FREEDOM Extension Study With Mild to Moderate Chronic Kidney Disease
CONTEXT: The effects of long-term exposure to denosumab in individuals with renal insufficiency are unknown. OBJECTIVE: This post hoc analysis evaluates the long-term safety and efficacy of denosumab in individuals with mild-to-moderate chronic kidney disease (CKD) (stages 2 and 3) using data from t...
Autores principales: | Broadwell, Aaron, Chines, Arkadi, Ebeling, Peter R, Franek, Edward, Huang, Shuang, Smith, Shawna, Kendler, David, Messina, Osvaldo, Miller, Paul D |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7823314/ https://www.ncbi.nlm.nih.gov/pubmed/33211870 http://dx.doi.org/10.1210/clinem/dgaa851 |
Ejemplares similares
-
Bone Mineral Density After Transitioning From Denosumab to Alendronate
por: Kendler, David, et al.
Publicado: (2019) -
The risk of subsequent osteoporotic fractures is decreased in subjects experiencing fracture while on denosumab: results from the FREEDOM and FREEDOM Extension studies
por: Kendler, D. L., et al.
Publicado: (2018) -
Long-term denosumab treatment restores cortical bone loss and reduces fracture risk at the forearm and humerus: analyses from the FREEDOM Extension cross-over group
por: Bilezikian, J.P., et al.
Publicado: (2019) -
The effect of 8 or 5 years of denosumab treatment in postmenopausal women with osteoporosis: results from the FREEDOM Extension study
por: Papapoulos, S., et al.
Publicado: (2015) -
Multiple Vertebral Fractures After Denosumab Discontinuation: FREEDOM and FREEDOM Extension Trials Additional Post Hoc Analyses
por: Cosman, Felicia, et al.
Publicado: (2022)